Currently, there is no disease-modifying treatment available for Alzheimer's and Parkinson's
disease (AD and PD) and that includes the highly controversial approval of the Aβ-targeting …

So far, the search for a cure for Alzheimer Disease (AD) has been unsuccessful. The only
approved drugs attenuate some symptoms, but do not halt the progress of this disease …

The physiological impact of the aberrant oxidation products on genomic DNA were
demonstrated by embryonic lethality or the cancer susceptibility and/or neurological …

Alzheimer's disease (AD) is the most common type of neurodegenerative disease. Its typical
pathology consists of extracellular amyloid-β (Aβ) plaques and intracellular tau …

Increasing numbers of cancer patients survive and live longer than five years after therapy,
but very often side effects of cancer treatment arise at same time. One of the side effects …

Mitochondria play key roles in ATP supply, calcium homeostasis, redox balance control and
apoptosis, which in neurons are fundamental for neurotransmission and to allow synaptic …

Support for the concept that herpes simplex virus type 1 (HSV1), when present in the brains
of apolipoprotein E‐«4 carriers, is a major risk for Alzheimer's disease (AD) is increasing …

Telomeres, also known as the “protective caps” of our chromosomes, shorten with each cell
cycle due to the end replication problem. This process, termed telomere attrition, is …

Alzheimer's disease (AD) is a progressive neurodegenerative disease that accounts for a
majority of dementia cases. AD is characterized by progressive neuronal death associated …

Alzheimer's disease (AD) is a progressive and deleterious neurodegenerative disease,
strongly affecting the cognitive functions and memory of seniors worldwide. Around 58% of …